| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
The molecular targets of Palmitoyl Tripeptide-8 are related to its role as a signaling peptide in the skin. As a biomimetic peptide based on α-MSH, it may interact with melanocortin receptors (MC1R) or other receptors involved in skin pigmentation and immune modulation. The peptide stimulates stromal cells, including fibroblasts, to increase the production of collagen (types I, II, and IV) and extracellular matrix proteins. This leads to improved skin structure, elasticity, and resilience. The peptide also has anti-allergen effects, suggesting it may modulate immune responses in the skin by reducing the release of pro-inflammatory mediators from mast cells and other immune cells. The palmitoyl chain enhances the peptide's affinity for the skin by facilitating its incorporation into cell membranes and improving its stability, allowing for prolonged activity at the target site. The peptide's mechanism of action is primarily through receptor-mediated signaling that promotes tissue repair and regeneration.
|
|---|---|
| ln Vitro |
In vitro activity of Palmitoyl Tripeptide-8 is characterized by its effects on skin cells and immune cells. In fibroblast cell cultures (e.g., human dermal fibroblasts), the peptide stimulates collagen synthesis at concentrations of 1-100 μg/mL, as measured by collagen type I and type III production (ELISA or Western blotting). The peptide also increases the expression of extracellular matrix proteins including fibronectin and elastin. In keratinocyte cultures, the peptide promotes cell proliferation and migration, which are important for wound healing and skin barrier repair. In immune cell cultures (e.g., mast cells, macrophages), the peptide reduces the release of histamine and pro-inflammatory cytokines (TNF-α, IL-6) in response to allergens or other stimuli, consistent with its anti-allergen effects. The peptide's activity is dose-dependent, with EC50 values typically in the low micromolar range. The palmitoyl chain enhances the peptide's cellular uptake and activity compared to the unconjugated peptide. Specific IC50 or EC50 values would need to be determined for each assay system.
|
| ln Vivo |
In vivo activity of Palmitoyl Tripeptide-8 has been demonstrated in clinical studies for skin care applications. In human clinical studies, topical application of formulations containing Palmitoyl Tripeptide-8 at concentrations of 0.1-1% for 4-12 weeks improves skin parameters including skin hydration, elasticity, firmness, and reduction of fine lines and wrinkles. The peptide's anti-allergen effects have been demonstrated in clinical studies where it reduces skin redness and irritation in response to UV exposure or chemical irritants. In animal models (e.g., hairless mice), topical application of the peptide reduces UV-induced skin damage, inflammation, and collagen degradation. The peptide's effects are cumulative, with continued use leading to progressive improvements in skin appearance and function. The peptide is widely used in cosmetic products for its anti-aging and soothing properties.
|
| Enzyme Assay |
For in vitro assays with Palmitoyl Tripeptide-8, the following protocols are used: For collagen synthesis assays, human dermal fibroblasts (HDFs) are cultured in DMEM with 10% FBS at 37°C in 5% CO₂. Cells are seeded in 24-well plates at 5 × 10⁴ cells per well and grown to 70-80% confluence. Cells are serum-starved for 24 hours and then treated with Palmitoyl Tripeptide-8 at concentrations of 1, 10, and 100 μg/mL for 24-72 hours. Culture supernatants are collected for collagen quantification by ELISA (human type I collagen, type III collagen). Cells are lysed for RNA extraction and qRT-PCR analysis of collagen genes (COL1A1, COL3A1) and other extracellular matrix genes (FN1, ELN, MMP1). For cell proliferation assays, cells are seeded in 96-well plates and treated with the peptide for 24-72 hours, and cell viability is assessed using the MTT or CellTiter-Glo assay. For anti-allergen assays, human mast cells (e.g., LAD2 cells) or RBL-2H3 cells are sensitized with IgE and then stimulated with antigen (e.g., DNP-BSA) in the presence or absence of the peptide. Histamine release is measured by ELISA. Cytokine release (TNF-α, IL-6, IL-8) is measured by ELISA. For UV protection studies, fibroblasts or keratinocytes are treated with the peptide and then exposed to UV radiation (UVA or UVB), and cell viability and ROS production are assessed.
|
| Animal Protocol |
For in vivo clinical studies with Palmitoyl Tripeptide-8, the following general protocol is used: human subjects (30-60 years old) with mild to moderate signs of skin aging are enrolled in a randomized, double-blind, vehicle-controlled study. The test product containing 0.1-1% Palmitoyl Tripeptide-8 and the vehicle control are applied topically to designated areas (e.g., face, forearm) twice daily for 4-12 weeks. Skin parameters are assessed at baseline and at regular intervals (2, 4, 8, 12 weeks). Skin hydration is measured using a corneometer. Skin elasticity and firmness are measured using a cutometer. Wrinkle depth and density are measured using a profilometer or 3D imaging system. Skin redness and irritation are assessed using a chromameter or by visual scoring. Subject self-assessment questionnaires are used to evaluate perceived improvements in skin appearance and feel. Biopsies may be collected for histological analysis (collagen staining, elastin staining) and gene expression analysis. For anti-allergen studies, subjects with sensitive skin are exposed to UV radiation or chemical irritants (e.g., sodium lauryl sulfate) in the presence or absence of the peptide, and skin redness and irritation are measured.
|
| Additional Infomation |
Palmitoyl Tripeptide-8 (CAS# 936544-53-5) is a synthetic peptide with a palmitoyl chain, based on α-MSH, with anti-allergen effects. It is a signal peptide that promotes collagen synthesis (types I, II, IV) and is used as a cosmetic ingredient. It has a molecular formula of C37H61N9O4. Future research could focus on elucidating the molecular mechanisms of its anti-allergen and anti-aging effects, optimizing its formulation for enhanced skin penetration and efficacy, and exploring its potential in therapeutic applications for skin disorders.
|
| Molecular Formula |
C37H61N9O4
|
|---|---|
| Molecular Weight |
695.938148260117
|
| Exact Mass |
695.484
|
| CAS # |
936544-53-5
|
| PubChem CID |
11498521
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5.9
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
28
|
| Heavy Atom Count |
50
|
| Complexity |
1000
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CCCCCCCCCCCCCCCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N
|
| InChi Key |
WBHUVOTYPRYBNG-QAXCHELISA-N
|
| InChi Code |
InChI=1S/C37H61N9O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-17-22-33(47)44-32(25-29-26-41-27-43-29)36(50)46-31(24-28-19-15-14-16-20-28)35(49)45-30(34(38)48)21-18-23-42-37(39)40/h14-16,19-20,26-27,30-32H,2-13,17-18,21-25H2,1H3,(H2,38,48)(H,41,43)(H,44,47)(H,45,49)(H,46,50)(H4,39,40,42)/t30-,31+,32-/m0/s1
|
| Chemical Name |
N-[(2S)-1-[[(2R)-1-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]hexadecanamide
|
| Synonyms |
L-Argininamide, N-(1-oxohexadecyl)-L-histidyl-D-phenylalanyl-
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4369 mL | 7.1845 mL | 14.3691 mL | |
| 5 mM | 0.2874 mL | 1.4369 mL | 2.8738 mL | |
| 10 mM | 0.1437 mL | 0.7185 mL | 1.4369 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
